Pharmaceutical manufacturers of Levosulpiride

SMS Lifesciences India Limited, headquartered in Hyderabad, India, is a research-driven company with over three decades of experience. It is a public listed leading API manufacturer, supplying to major generic and innovator firms. With a focus on APIs, the company operates four state-of-the-art facilities and provides quality alternative manufacturing solutions to multinational companies for their contract research and manufacturing needs. The company has multiple manufacturing facilities supporting a wide range and capacity of APIs and Intermediates.

Situated in Hyderabad, India, Symed Labs Ltd is a prominent and innovative producer of Active Pharmaceutical Ingredients (APIs) & a comprehensive solution provider for the pharmaceutical sector for chemistry related services. Symed labs has autonomously created processes for more than fifty APIs across various therapeutic categories in the laboratory and upscaled them to plant, as well as vending them to over 600 clients in 30 nations in the regulated and less regulated markets

Viyash embodies integrity and guidance in all aspects. As a fully-integrated pharmaceutical firm, we possess a robust collection of unique formulations, APIs, and advanced intermediates. Viyash and its affiliated companies manage 10 API/Intermediate facilities, boasting a combined capacity of approximately 2000 KL and diverse capabilities across various categories - small/large volume, potent/non-potent, regulated/semi-regulated markets. Additionally, we oversee a formulation manufacturing facility in New Jersey, USA, with a capacity of around 1.2 billion units.

We, at TIEFENBACHER GROUP, are driven by a deep sense of purpose: we are pioneering healthcare to improve patients’ lives around the world. We believe that the access to affordable high quality-healthcare is a human right. We always challenge the status quo to be one step ahead – in terms of business models as well as concrete products and services. This entrepreneurial spirit is the driving force of making high-quality pharmaceuticals more affordable, more available, and better than before. 100% family owned since 1963, we are a purpose-driven healthcare company providing best-in-class solutions throughout the entire pharmaceutical value chain. From initial idea to market access: We distribute raw materials and develop, manufacture, and register finished dosage forms like tablets, capsules, powders, drops, and patches as well as medical devices. This broad competence enables us to pioneer healthcare holistically as we can connect ideas and expertise to create novel healthcare solutions. By working together as TIEFENBACHER GROUP, in agile collaboration and cross-functional structures, we tap into our full potential and stay at the forefront of our field.

CBC offers outsourcing services for a diverse range of active pharmaceutical ingredients (API) and intermediates, and is also involved in the trade of agrochemical compounds. Additionally, CBC is expanding its operations to include manufacturing, utilizing cutting-edge technology and original research in collaboration with partner companies in each sector. With a focus on health, safety, and convenience, the company is actively engaged in Fine Chemicals, Pharmaceuticals, and Agrochemicals. Its services encompass the supply of the aforementioned products from various sources, support for contract manufacturing of advanced intermediates and bulk actives, as well as representation of various named chemicals and pharmaceutical manufacturers.

Our aim is to become a prominent company in the API and key intermediates industry. Established in 1994, our company is a certified GMP enterprise, specializing in the manufacturing of APIs (Active Pharmaceutical Ingredients), key intermediates of APIs, and fine chemicals. We pride ourselves on delivering high-quality products (APIs and key intermediates) that are meticulously prepared under stringent quality control and exceptional process management. Furthermore, we are a dynamic venture company striving to emerge as a global leader in the generic API industry. Through continuous research and development, we are enhancing our research capabilities and proprietary technology.

Established in the year 2000 as Dongwoo Shintech Co., Ltd., INIST ST has emerged as a pioneer in the advancement of pharmaceutical raw materials and the technology for synthesizing raw materials. Guided by the principles of transformation, innovation, and a passion for life, INIST ST has been engaged in the exploration and production of high-caliber generic raw materials and enhanced drugs through salt modification, commencing with the development of treatments for cerebrovascular diseases and distributing them both nationally and globally. Backed by unwavering trust and expertise, it is utilized as a contrast agent for heart disease and serves as the basis for numerous original active ingredients.

Kimia Biosciences, established in 1993, specializes in the production of bulk drugs for various medical segments. With a strong focus on quality and advanced technologies, Kimia aims to achieve global recognition in the production of both APIs and FDFs, while maintaining ethical business practices. The state-of-the-art facilities at Village Bhondsi, Gurugram enable the production of a wide range of APIs. Additionally, Kimia plans to develop its own facilities for lifestyle segments, adhering to international regulatory standards, with the goal of delivering top-quality pharmaceutical products and support to both consumers and healthcare professionals.

Leading Italian expert in personalized development and contract manufacturing of Active Pharmaceutical Ingredients, ICROM is the exclusive firm for APIs. Utilizing advanced expertise, ICROM constructs high-tech solutions for synthesizing intricate molecules and creating adaptable, expandable, and economical processes tailored to clients’ requirements. With varying production capacities in 4 cutting-edge manufacturing facilities sanctioned by AIFA, USFDA, PMDA, KFDA, ICROM is the preferred partner for CDMO of NCEs, advanced generics, and your drive for innovation.

KyungDong Pharm is making progress on a global scale. Established in 1975, KyungDong Pharm has been dedicated to developing ethical medicines and creating its own technologies for medicine development, previously reliant on imports. With the belief of leading human health and happiness through sincere and diligent efforts in medicine creation and development, the company has been actively involved in research and development. Currently, it contributes to the health of the Korean population by producing approximately 90 types of ethical medicines, pharmaceutical ingredient medicine, and non-prescription medicine.

DONGWHA PHARM, the earliest established pharmaceutical corporation in Korea established in 1897, has been involved in the advancement, manufacturing, distribution, and promotion of ethical medications such as solid dosage forms and sterile injectables, APIs, non-prescription drugs, dietary supplements, health products, and beauty products

Hwail Pharm is a South Korean pharmaceutical company established in 1980. They operate in two main areas: Pharmaceutical Raw Materials: Hwail Pharm manufactures and distributes various ingredients used in the production of medications, including antitussives, expectorants, and anti-inflammatories. Finished Formulations: They also produce and sell finished pharmaceutical products, such as injection solutions like ceftazidime and cefoperazone. The company has its headquarters in Hwaseong, South Korea, and is a significant player in the South Korean pharmaceutical market. They prioritize quality and adhere to international standards in their manufacturing and distribution processes. Additionally, they offer food ingredients beyond pharmaceuticals.

Established in April 1992, SAMO' was founded with the primary goal of advancing the pharmaceutical sector across all nations during the era of independence. Consequently, the company has created 32 employment opportunities and has engaged local industry professionals. Presently, the organization collaborates with medical experts, professors, as well as members of the International Academy of Ecology and Life Safety, possessing dual PhDs and highly skilled personnel. The future of the pharmaceutical field greatly relies on the types and quantities of medications, along with their appropriateness for the population's needs.

Medochemie functions as an international pharmaceutical organization specializing in the development, production, and distribution of Generics. Its main offices are located in Cyprus, and it maintains a network of 19 affiliated companies across Europe and other regions. The company has a workforce of 1,940 highly trained experts, possesses 5145 marketing authorizations, and operates 13 manufacturing facilities in Cyprus, The Netherlands, and Vietnam, all of which are constructed to adhere to the prevailing Good Manufacturing Practices (cGMPs) established by the European and WHO regulatory bodies